Speaker Profile
Ph.D., CEO, GeneScape
Biography
Karen Malone is dedicated closing the gap in drug development strategies for innovative, personalized therapies, by mapping the unmet need for inherited rare, ultra-rare, and orphan diseases. She founded GeneScape® to help inform drug development planning, with the goal of accelerating advanced therapeutics to these patients. GeneScape® leverages the latest in large-scale human genetic diversity data and machine learning tools to provide actionable data and reliable patient models to address some of the most challenging rare diseases.
Dr. Malone is a molecular biologist and geneticist with a track-record of over 15 years of drug development experience, including prior scientific roles at Janssen Pharmaceuticals. Her work has covered the entire development path from discovery to pivotal trials, and new product planning. She has supported the development of a range of therapeutic modalities including genetic therapies for numerous indications and published more than 11 scientifically peer-reviewed papers.
Talk
GeneScape: Mapping Inherited Rare Disease Patient Populations
Dr. Malone will present GeneScape’s platform and recent examples of how their research has informed various programs by 1) quantifying the scale of unmet need, 2) estimating specific patient subsets, 3) identifying highest probability regions for finding patients, and 5) understanding the importance of patient genetic diversity within specific indications.
AI and Data Sciences Showcase:
GeneScape
GeneScape® is specialized in epidemiology for inherited rare, ultra-rare and orphan diseases. We leverage the latest in large-scale genetic diversity data to deliver actionable insights to streamline drug development. GeneScape® is a compass to navigate and transform your programs for rare, ultra-rare and orphan diseases.
Session Abstract – PMWC 2024 Silicon Valley
The PMWC 2024 AI Company Showcase will provide a 15-minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.
